CD274 and non-small cell lung carcinoma: For example, KEYNOTE-024 showed a significant benefit of pembrolizumab as first-line monotherapy comparing to platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression over 50%, in both response rate and OS [83, 84].